Pay in 4 interest-free payments of $29.75 Learn more
Ships within 48 hours · Estimated delivery Jul 27 - Aug 1
Development and binding mode assessment of N-[4-[2-propyn-1-yl[(6S)-4
49-32)35-23(3)16-31(47-35)34-22(2)15-24(4)39(44
can diminish the inhibitory effects of chondroitin sulfate proteoglycans (CSPGs)
Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases: in vitro studies on antioxidant activity
Ganaraja B
(S)-CCG-1423 Catalog No.:M23385-C Development and binding mode assessment(S) CCG 1423 is a stereoisomer of CCG 1423. CCG 1423 is a Rho inhibitor involved in blocking signaling through myocardin related transcription factor A (MRTF A) and serum response factor (SRF) . The Rho family of small GTPases plays an important role in cancer metastasis. Up regulation of RhoA or RhoC has been associated with a poor clinical outcome. Rho GTPases are important for the actin cytoskeleton. The RhoA family plays an important role in